Plain-English translation of NCT06765161 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called efgartigimod to see if it can work as well as the current standard treatment (IVIG infusions) for people with myasthenia gravis—a condition that causes muscle weakness. The medication is given as a weekly infusion into your vein. Researchers want to know if this treatment is easier, safer, or more convenient than what you're currently receiving.
Many people with myasthenia gravis depend on regular IVIG infusions to manage their symptoms, but this treatment can be inconvenient and may have side effects. Researchers believe this new medication might offer a better option that works just as well or better.
You likely qualify if…
You likely don't qualify if…
You will receive weekly infusions of the medication through an IV for four weeks, then take a four-week break, and repeat this cycle four times over six months. Your other myasthenia gravis medications will stay the same during the study. You'll be asked to stop your current IVIG treatment one week before the study starts. The study lasts 26 weeks total, with regular visits to check how you're doing and monitor for any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Canada
Phase
Large-scale testing
Sponsor
Clinique Neuro-Outaouais
Collaborators
argenx
Enrollment target
~30 participants
Started
February 2025
Primary completion
January 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
François Jacques, Doctor
Clinique Neuro-Outaouais
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.